Disulfiram: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Disulfiram (Antabuse) |FDA_approval=Yes (for preventing alcohol consumption) |used_for=Exploratory treatment for GBM in combination with temozolomide and potentially copper gluconate |clinical_trial_phase=Phase I pharmacodynamics trial at Washington University, ongoing research |common_side_effects=At higher doses: delirium and peripheral motor neuropathy; minimal toxicity when alcohol is not consumed |OS_without=Not specified |OS_with=Early re...") |
No edit summary Tag: Manual revert |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 11: | Line 11: | ||
|usefulness_rating=3 | |usefulness_rating=3 | ||
|notes=Disulfiram, a drug traditionally used to prevent alcohol consumption, shows promise in GBM treatment through mechanisms such as blocking glycoprotein pumps and inhibiting MGMT enzyme and metalloproteinase activity. It's believed to inhibit the growth of cancer stem cells, a major source of treatment failures. Its anticancer effects may be potentiated by concurrent use of copper gluconate. Current trials are investigating optimal dosing and combination strategies to maximize therapeutic outcomes. | |notes=Disulfiram, a drug traditionally used to prevent alcohol consumption, shows promise in GBM treatment through mechanisms such as blocking glycoprotein pumps and inhibiting MGMT enzyme and metalloproteinase activity. It's believed to inhibit the growth of cancer stem cells, a major source of treatment failures. Its anticancer effects may be potentiated by concurrent use of copper gluconate. Current trials are investigating optimal dosing and combination strategies to maximize therapeutic outcomes. | ||
| | |treatment_category=Repurposed Drugs | ||
|links= | |links= | ||
|toxicity_level=2 | |||
|toxicity_explanation=Disulfiram shows a relatively low toxicity for treating Glioblastoma, especially when no alcohol is consumed. This means it could be a safer choice for treatment. Potential side effects like delirium and peripheral motor neuropathy were only reported at higher dosages. However, ongoing research is important to maximize therapeutic outcomes and minimize any potential side effects. | |||
}} | }} | ||
Latest revision as of 10:58, 12 November 2024
| Property | Information |
|---|---|
| Drug Name | Disulfiram (Antabuse) |
| FDA Approval | Yes (for preventing alcohol consumption) |
| Used for | Exploratory treatment for GBM in combination with temozolomide and potentially copper gluconate |
| Clinical Trial Phase | Phase I pharmacodynamics trial at Washington University, ongoing research |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | At higher doses: delirium and peripheral motor neuropathy; minimal toxicity when alcohol is not consumed |
| OS without | Not specified |
| OS with | Early results suggest potential efficacy in enhancing chemotherapy response; ongoing trials |
| PFS without | Not specified |
| PFS with | Initial results indicate a need for dosage optimization to balance efficacy and side effects |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | Disulfiram shows a relatively low toxicity for treating Glioblastoma, especially when no alcohol is consumed. This means it could be a safer choice for treatment. Potential side effects like delirium and peripheral motor neuropathy were only reported at higher dosages. However, ongoing research is important to maximize therapeutic outcomes and minimize any potential side effects. |
Notes: Disulfiram, a drug traditionally used to prevent alcohol consumption, shows promise in GBM treatment through mechanisms such as blocking glycoprotein pumps and inhibiting MGMT enzyme and metalloproteinase activity. It's believed to inhibit the growth of cancer stem cells, a major source of treatment failures. Its anticancer effects may be potentiated by concurrent use of copper gluconate. Current trials are investigating optimal dosing and combination strategies to maximize therapeutic outcomes.
From Ben Williams Book: Not specified
Loading comments...
